Hirschfeld Oncology

Brooklyn, New York 11206

2 studies enrolling now · 3 studies all time

What they study most

BRAF Gene Mutation, Bladder Cancer, Cholangiocarcinoma, Colorectal Cancer, ERK Mutation, Esophageal Cancer, Gastric Cancer, Glioblastoma, HRAS Gene Mutation, Head and Neck Cancer, Hepatocellular Carcinoma, KRAS Activating Mutation

Studies at this site

• Expanded Access Program for Daraxonrasib (RMC-6236) in Previously Treated Metastatic Pancreatic Adenocarcinoma — Available (expanded access)
• Expanded Access to Ulixertinib (BVD-523) in Patients With Advanced MAPK Pathway-Altered Malignancies — Available (expanded access)
• Evaluate Efficacy of Devimistat in Combination With mFFX in 2nd Line Patients With Metastatic Pancreatic Cancer — Withdrawn before enrolling